|
Aug 6
|
Citi ups Syndax target, opens ‘upside catalyst watch’
|
|
Aug 6
|
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 4
|
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 4
|
Syndax: Q2 Earnings Snapshot
|
|
Aug 4
|
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 29
|
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
|
|
Jul 29
|
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
|
|
Jul 29
|
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
|
|
Jul 28
|
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
|
|
Jun 24
|
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
|
|
Jun 24
|
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial
|
|
Jun 13
|
Syndax reports publication of revumenib data from BEAT AML trial
|
|
Jun 12
|
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
|
|
Jun 12
|
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
|
|
Apr 2
|
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
|
|
Feb 24
|
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
|
|
Feb 20
|
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
|
|
Jul 29
|
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
|
|
Jul 29
|
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
|
|
Jul 25
|
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
|